AI assistant
Sending…
Cartesian Therapeutics, Inc. — Director's Dealing 2021
May 11, 2021
33483_dirs_2021-05-11_d29d9c4a-4334-4a5e-9751-062a7f7dece7.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: SELECTA BIOSCIENCES INC (SELB)
CIK: 0001453687
Period of Report: 2021-05-07
Reporting Person: Kishimoto Takashi Kei (Chief Scientific Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-05-07 | Common Stock | M | 13629 | $2.77 | Acquired | 177778 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-05-07 | Employee Stock Option (right to buy) | $2.77 | M | 13629 | Disposed | 2021-09-07 | Common Stock (13629.0) | Direct |
Footnotes
F1: The option is fully vested as of September 7, 2015.
More from Cartesian Therapeutics, Inc.
Regulatory Filings
2026
May 26
Regulatory Filings
2026
Apr 30
Interim / Quarterly Report
2026
Apr 30
Regulatory Filings
2026
Apr 30
Proxy Solicitation & Information Statement
2026
Apr 28
Regulatory Filings
2026
Mar 30
Major Shareholding Notification
2026
Feb 5
Regulatory Filings
2026
Jan 9
Director's Dealing
2026
Jan 8
Director's Dealing
2026
Jan 8